Navidea Biopharmaceuticals, Inc. (NAVB) |
|
0.0853 -0.005 (-5.22%)
|
06-06 14:42 |
|
Open: |
0.0848 |
Pre. Close: |
0.09 |
|
High:
|
0.0888 |
Low:
|
0.0833 |
|
Volume:
|
1,097,636 |
Market Cap:
|
3(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 2:19:44 PM |
|
Short-term rate:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 0.19  One year: 0.25 |
| Support: |
Support1: 0.07 Support2: 0.06 |
| Resistance: |
Resistance1: 0.16 Resistance2: 0.21 |
| Pivot: |
0.1 |
| Moving Average: |
MA(5): 0.09 MA(20): 0.11
MA(100): 0.24 MA(250): 0.33 |
| MACD: |
MACD(12,26): -0.1  Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 16.3 %D(3): 18.2 |
| RSI: |
RSI(14): 30.8 |
| 52-week: |
High: 0.93 Low: 0.07 |
| Average Vol(K): |
3-Month: 2,210 (K) 10-Days: 10,579 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NAVB ] has closed above bottom band by 19.8%. Bollinger Bands are 37.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.1 - 0.1 |
0.1 - 0.1 |
|
Low:
|
0.08 - 0.08 |
0.08 - 0.08 |
|
Close:
|
0.08 - 0.08 |
0.08 - 0.09 |
|
Company Description |
|
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio. |
Headline News |
Mon, 05 Jun 2023
Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice - Marketscreener.com
Fri, 02 Jun 2023
Navidea Biopharmaceuticals, Inc. (NAVB) Stock Price Today, Quote ... - Seeking Alpha
Tue, 23 May 2023
Why Microvast Holdings Shares Are Trading Lower By Around 22 ... - Investing.com UK
Tue, 23 May 2023
Financings for May 23, 2023 - BioWorld Online
Mon, 22 May 2023
Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market - Yahoo Finance
Mon, 08 May 2023
Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
